Home
 /
Papers
 /
Immunology
 /
Structural insights into antibody responses against influenza A virus in its natural reservoir
Preprint
Open access
V1
Top 1% · Validated by QED

Structural insights into antibody responses against influenza A virus in its natural reservoir

Huibin Lv, Walter N. Harrington, Wenkan Liu +24 more
March 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.03.11.711171
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Immunology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

Resolving a long-standing paradox in influenza evolution, this study reveals duck antibodies suppress H3 antigenic drift through glycan-targeted neutralization, CDR H3-independent binding, and a decoy-receptor mechanism, reframing how natural reservoirs shape viral stability.

QED claims analysis

Summary

Mallard duck antibody responses to influenza H3 hemagglutinin exhibit unique features including a propensity to generate neutralizing antibodies that primarily target N-glycans, a balanced immunodominance hierarchy across multiple head domain antigenic sites, and convergent binding modes enabled by gene conversion, which collectively explain the antigenic stability of influenza A virus in its natural waterfowl reservoir despite sustained immune pressure.

See full analysis
Main Claim 1 –

Mallard Ducks Generate Neutralizing HA N-Glycan-Targeting Antibodies

Supporting evidence

  • Mallards Have Expanded Functional IGLV Genes and Pseudogenes
  • N-Glycosylated CDR H3 Mimics Receptor to Bind HA RBS
Main Claim 2 –

Duck Stem Antibodies Convergently Target HA1 N22 Glycan

Supporting evidence

  • HA1 N22 Glycan Is Conserved and Replication-Critical in Group 2
Main Claim 3 –

Duck Antibodies Show Balanced Targeting of HA Head Sites

Supporting evidence

  • Gene Conversion Enables Convergent CDR H3-Independent Duck Antibodies

Abstract

While influenza A virus undergoes rapid antigenic drift in humans, at least some subtypes, such as H3, have relatively stable antigenicity in natural waterfowl reservoirs, despite the presence of immune pressure. However, the underlying mechanisms remain poorly understood. This study identified and characterized 187 antibodies to H3 hemagglutinin from experimentally infected mallard ducks, 18 of which were further analyzed by cryo-EM. Compared with human H3 antibodies, duck H3 antibodies exhibited higher glycan-binding propensity, more balanced immunodominance hierarchy, and targeted distinct epitopes. Other unique features of duck H3 antibodies included a convergent CDR H3-independent heavy chain-only binding mode and an N-glycosylated CDR H3 as decoy receptor. By annotating duck immunoglobulin germline genes, we also demonstrated the importance of gene conversion in duck H3 antibodies. Overall, our findings provide insights into how millennia of coevolution have shaped the interplay between influenza A virus antigenic drift and antibody responses in the natural reservoir.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?